Engineered Liver Platforms for Different Phases of Drug Development

Overview

Journal Trends Biotechnol

Specialty Biochemistry

Date 2016 Sep 6

PMID 27592803

Citations 32

Authors

Brenton R Ware

Salman R Khetani

Affiliations

Soon will be listed here.

Abstract

Drug-induced liver injury (DILI) remains a leading cause of drug withdrawal from human clinical trials or the marketplace. Owing to species-specific differences in liver pathways, predicting human-relevant DILI using in vitro human liver models is crucial. Microfabrication tools allow precise control over the cellular microenvironment towards stabilizing liver functions for weeks. These tools are used to engineer human liver models with different complexities and throughput using cell lines, primary cells, and stem cell-derived hepatocytes. Including multiple human liver cell types can mimic cell-cell interactions in specific types of DILI. Finally, organ-on-a-chip models demonstrate how drug metabolism in the liver affects multi-organ toxicities. In this review we survey engineered human liver platforms within the needs of different phases of drug development.

Citing Articles

Chemogenomic Screening in a Patient-Derived 3D Fatty Liver Disease Model Reveals the CHRM1-TRPM8 Axis as a Novel Module for Targeted Intervention.

Youhanna S, Kemas A, Wright S, Zhong Y, Klumpp B, Klein K Adv Sci (Weinh). 2024; 12(3):e2407572.

PMID: 39605182 PMC: 11744578. DOI: 10.1002/advs.202407572.

Organ-on-a-Chip: ? Fundamentals and Design Aspects.

Morais A, Mendes M, Cordeiro M, Sousa J, Pais A, Mihaila S Pharmaceutics. 2024; 16(5).

PMID: 38794277 PMC: 11124787. DOI: 10.3390/pharmaceutics16050615.

Mechanistic Understanding of Idiosyncratic Drug-Induced Hepatotoxicity Using Co-Cultures of Hepatocytes and Macrophages.

Villanueva-Badenas E, Donato M, Tolosa L Antioxidants (Basel). 2023; 12(7).

PMID: 37507855 PMC: 10376129. DOI: 10.3390/antiox12071315.

Development of a Hybrid Polymer-Based Microfluidic Platform for Culturing Hepatocytes towards Liver-on-a-Chip Applications.

Kulsharova G, Kurmangaliyeva A, Darbayeva E, Rojas-Solorzano L, Toxeitova G Polymers (Basel). 2021; 13(19).

PMID: 34641031 PMC: 8513053. DOI: 10.3390/polym13193215.

Development of improved SRC-3 inhibitors as breast cancer therapeutic agents.

Qin L, Chen J, Lu D, Jain P, Yu Y, Cardenas D Endocr Relat Cancer. 2021; 28(10):657-670.

PMID: 34310341 PMC: 8404148. DOI: 10.1530/ERC-20-0402.

References

Chao P, Maguire T, Novik E, Cheng K, Yarmush M . Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem Pharmacol. 2009; 78(6):625-32. PMC: 4487512. DOI: 10.1016/j.bcp.2009.05.013. View

Allen J, Khetani S, Bhatia S . In vitro zonation and toxicity in a hepatocyte bioreactor. Toxicol Sci. 2004; 84(1):110-9. DOI: 10.1093/toxsci/kfi052. View

Leclerc E, Hamon J, Legendre A, Bois F . Integration of pharmacokinetic and NRF2 system biology models to describe reactive oxygen species production and subsequent glutathione depletion in liver microfluidic biochips after flutamide exposure. Toxicol In Vitro. 2014; 28(7):1230-41. DOI: 10.1016/j.tiv.2014.05.003. View

Lee D, Lee M, Ku B, Yi S, Ryu J, Jeon R . Application of the DataChip/MetaChip technology for the evaluation of ajoene toxicity in vitro. Arch Toxicol. 2013; 88(2):283-90. DOI: 10.1007/s00204-013-1102-9. View

Baudoin R, Prot J, Nicolas G, Brocheton J, Brochot C, Legallais C . Evaluation of seven drug metabolisms and clearances by cryopreserved human primary hepatocytes cultivated in microfluidic biochips. Xenobiotica. 2012; 43(2):140-52. DOI: 10.3109/00498254.2012.706725. View

Baudoin R, Legendre A, Jacques S, Cotton J, Bois F, Leclerc E . Evaluation of a liver microfluidic biochip to predict in vivo clearances of seven drugs in rats. J Pharm Sci. 2013; 103(2):706-18. DOI: 10.1002/jps.23796. View

Ploss A, Khetani S, Jones C, Syder A, Trehan K, Gaysinskaya V . Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci U S A. 2010; 107(7):3141-5. PMC: 2840339. DOI: 10.1073/pnas.0915130107. View

Nguyen T, Ukairo O, Khetani S, McVay M, Kanchagar C, Seghezzi W . Establishment of a hepatocyte-kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters. Drug Metab Dispos. 2015; 43(5):774-85. DOI: 10.1124/dmd.114.061317. View

Nakao Y, Kimura H, Sakai Y, Fujii T . Bile canaliculi formation by aligning rat primary hepatocytes in a microfluidic device. Biomicrofluidics. 2011; 5(2):22212. PMC: 3145237. DOI: 10.1063/1.3580753. View

10.

Shih M, Tseng S, Weng Y, Chu I, Liu C . A microfluidic device mimicking acinar concentration gradients across the liver acinus. Biomed Microdevices. 2013; 15(5):767-80. DOI: 10.1007/s10544-013-9762-z. View

11.

Prodanov L, Jindal R, Bale S, Hegde M, McCarty W, Golberg I . Long-term maintenance of a microfluidic 3D human liver sinusoid. Biotechnol Bioeng. 2015; 113(1):241-6. PMC: 4967935. DOI: 10.1002/bit.25700. View

12.

Zhou Q, Patel D, Kwa T, Haque A, Matharu Z, Stybayeva G . Liver injury-on-a-chip: microfluidic co-cultures with integrated biosensors for monitoring liver cell signaling during injury. Lab Chip. 2015; 15(23):4467-78. DOI: 10.1039/c5lc00874c. View

13.

Davidson M, Lehrer M, Khetani S . Hormone and Drug-Mediated Modulation of Glucose Metabolism in a Microscale Model of the Human Liver. Tissue Eng Part C Methods. 2014; 21(7):716-25. PMC: 4499785. DOI: 10.1089/ten.TEC.2014.0512. View

14.

Bavli D, Prill S, Ezra E, Levy G, Cohen M, Vinken M . Real-time monitoring of metabolic function in liver-on-chip microdevices tracks the dynamics of mitochondrial dysfunction. Proc Natl Acad Sci U S A. 2016; 113(16):E2231-40. PMC: 4843487. DOI: 10.1073/pnas.1522556113. View

15.

Kmiec Z . Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol. 2001; 161:III-XIII, 1-151. DOI: 10.1007/978-3-642-56553-3. View

16.

Kasuya J, Sudo R, Mitaka T, Ikeda M, Tanishita K . Spatio-temporal control of hepatic stellate cell-endothelial cell interactions for reconstruction of liver sinusoids in vitro. Tissue Eng Part A. 2012; 18(9-10):1045-56. DOI: 10.1089/ten.TEA.2011.0351. View

17.

Frey O, Misun P, Fluri D, Hengstler J, Hierlemann A . Reconfigurable microfluidic hanging drop network for multi-tissue interaction and analysis. Nat Commun. 2014; 5:4250. DOI: 10.1038/ncomms5250. View

18.

Prueksaritanont T, Chu X, Gibson C, Cui D, Yee K, Ballard J . Drug-drug interaction studies: regulatory guidance and an industry perspective. AAPS J. 2013; 15(3):629-45. PMC: 3691435. DOI: 10.1208/s12248-013-9470-x. View

19.

Sung J, Kam C, Shuler M . A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip. 2010; 10(4):446-55. DOI: 10.1039/b917763a. View

20.

Miyamoto Y, Ikeuchi M, Noguchi H, Yagi T, Hayashi S . Spheroid Formation and Evaluation of Hepatic Cells in a Three-Dimensional Culture Device. Cell Med. 2016; 8(1-2):47-56. PMC: 4733911. DOI: 10.3727/215517915X689056. View